Mosunetuzumab + Polatuzumab Vedotin for Aggressive B-Cell Lymphoma
(SUNMO Trial)
Trial Summary
What is the purpose of this trial?
This study will assess the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin (M+P) in participants with relapsed or refractory (R/R) diffuse-large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, transformed follicular lymphoma (trFL) and FL Grade 3B (FL3B) in comparison with a commonly used regimen in this participant population, rituximab, gemcitabine and oxaliplatin (R-GemOx).
Do I need to stop my current medications to join the trial?
The trial protocol does not specify if you need to stop taking your current medications. However, it mentions that you should not have received certain anti-lymphoma treatments or other investigational therapies shortly before starting the study treatment.
What data supports the effectiveness of the drug combination Mosunetuzumab and Polatuzumab Vedotin for treating aggressive B-cell lymphoma?
Polatuzumab vedotin, when combined with rituximab, has shown significant clinical activity in treating relapsed or refractory diffuse large B-cell lymphoma, which is a type of aggressive B-cell lymphoma. This combination has been effective in patients who have not responded to other treatments, suggesting potential effectiveness for similar conditions.12345
Is the combination of Mosunetuzumab and Polatuzumab Vedotin safe for humans?
Polatuzumab vedotin has been studied in various clinical trials for B-cell lymphomas, and the risk of developing anti-drug antibodies (which can affect how the body responds to the drug) is considered low. This suggests that the treatment is generally safe for humans, as the low incidence of these antibodies is not expected to impact the overall safety profile.15678
What makes the drug combination of Mosunetuzumab and Polatuzumab Vedotin unique for treating aggressive B-cell lymphoma?
This treatment is unique because it combines Mosunetuzumab, a bispecific antibody that targets CD20 and CD3 to engage T-cells, with Polatuzumab Vedotin, an antibody-drug conjugate targeting CD79b on B-cells, offering a novel dual-targeting approach that may enhance the immune system's ability to attack lymphoma cells.12789
Research Team
Clinical Trials
Principal Investigator
Hoffmann-La Roche
Eligibility Criteria
This trial is for adults with certain aggressive B-cell non-Hodgkin's lymphomas that have come back or didn't respond to previous treatments. They should be relatively active (ECOG 0-2), not eligible for stem cell transplant if only one prior therapy was received, and must have measurable disease. People with HIV can join if stable on treatment, but those with recent other cancer treatments, major infections, heart or lung issues, CNS involvement of lymphoma, severe allergies to monoclonal antibodies or autoimmune diseases cannot participate.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive mosunetuzumab and polatuzumab vedotin or rituximab, gemcitabine, and oxaliplatin over multiple cycles
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Mosunetuzumab
- Polatuzumab vedotin
- Rituximab
Mosunetuzumab is already approved in European Union, United States for the following indications:
- Relapsed or refractory follicular lymphoma after two or more lines of systemic therapy
- Relapsed or refractory follicular lymphoma after two or more lines of systemic therapy
Find a Clinic Near You
Who Is Running the Clinical Trial?
Hoffmann-La Roche
Lead Sponsor
Dr. Levi Garraway
Hoffmann-La Roche
Chief Medical Officer since 2019
MD from the University of Basel
Dr. Thomas Schinecker
Hoffmann-La Roche
Chief Executive Officer since 2023
PhD in Molecular Biology from New York University